S. Aliberti (Milano, Italy), M. Tamm (Basel, Switzerland)
Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients
N. Miyashita, M. Kubo, Y. Kawai, K. Ouchi, N. Okimoto (Okayama, Japan)
|  |
Clarithromycin inhibits pandemic A/H1N1/2009 influenza virus infection in human airway epithelial cells
M. Yamaya, Y. Hatachi, H. Kubo, H. Nishimura (Sendai, Kyoto, Japan)
| |
Community-acquired pneumonia in five European countries: Usage patterns and real-life effectiveness of antibiotics (REACH study)
F. Blasi, J. Garau, J. Medina, M. Ávila, K. McBride, H. Ostermann (Milan, Italy; Barcelona, Madrid, Spain; Zaventem, Belgium; Chatham, United States Of America; Munich, Germany)
|  |
Caspofungin to treat invasive pulmonary aspergillosis in sarcoidosis
B. Garfield, G. Keir, M. Anwar, M. Loebinger, R. Wilson, E. Renzoni, A. Wells, T. Maher (London, United Kingdom)
| |
Macrolides vs quinolones in Legionella pneumonia treatment: CAPAVANT group. Valencia (Spain)
S. Herrera, E. Fernández, A. Cervera, M. C. Aguar, F. Sanz, J. Blanquer, E. Chiner (Valencia, Alicante, Spain; Valencia, Sri Lanka)
| |
Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia
N. Miyashita, Y. Kawai, M. Kubo, K. Ouchi, N. Okimoto (Okayama, Japan)
| |
Comparative study of community-acquired pneumonia between diabetic and nondiabetic patients with hyperglycemia
A. Urrutia, R. Zalacain, A. Gomez, L. Martinez-Indart, C. Jaca, M. Alfonso, R. Diez, M. Inchausti, L.A. Ruiz (Barakaldo, Spain)
| |
Factors associated with compliance with palivizumab treatment in the Canadian rSV evaluation study for synagis (CARESS) registry (32005-2011)
I. Mitchell, B. Paes, A. Li, K. Lanctot (Hamilton, Canada)
| |
Therapeutic outcomes for cavitary Mycobacterium avium complex (MAC) lung disease
D. Griffith, B. Brown-Elliott, S. Shepherd, J. Philley, R. Wallace (Tyler, United States Of America)
| |
Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia
S.C. Park, Y.A. Kang, B.H. Park, E.Y. Kim, M.S. Park, Y.S. Kim, S.K. Kim, J. Chang, J.Y. Jung (Seoul, Republic Of Korea)
| |
Invasive pulmonary aspergillosis: What is the role of surgery in the voriconazole era?
M. Neuville, A. Bergeron, P. Ribaud, E. Raffoux, B. Maitre, D. Gossot (Paris, Créteil, France)
| |
Rates of ophthalmic complications due to ethambutol in patients with non-tuberculous mycobacteria
A. Malem, H. Barker, N. Shafi, D. Wat, C. Haworth, R. A. Floto (Cambridge, United Kingdom)
| |
Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study
E. Polverino, C. Cilloniz, A. Gabarrus, S. Ewig, T. Welte, O. Rajas, A. Capelastegui, J. Almirall, A. Torres (Barcelona, Madrid, Maresme, Spain; , ; Hanover, Germany)
| |
Antibacterial therapy of community-acquired pneumonia (CAP) at patients with cardiovascular diseases (CVD)
H. Demchuk, Y. Mostovoy (Vinnytsia, Ukraine)
| |
Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia
S. Hanada, S. Suzuki, H. Uruga, H. Takaya, A. Miyamoto, N. Morokawa, A. Kurosaki, K. Kishi (Minato-ku, Japan)
| |
The spectrum of bacterial resistance in the lower respiratory tract infections in Oradea Pneumology Hospital in 2011
L. Davidescu, N. Zaporojean (Oradea, Romania)
| |
Pulmonary nocardiosis in a teaching hospital in the Central Anatolia of Turkey: Clinical experience in 26 patients
F.S. Oymak, N. Tutar, D. Percin, O. Yildiz, A. Unal, A. Yildirim, F. Kurnaz, A. Kanbay, H. Buyukoglan, I. Gulmez, R. Demir (Kayseri, Turkey)
| |